A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s Disease
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment - InCharge A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, ph ...